Expand REPL Menu
REPL MENU

REPL Latest Press Releases

-- August 7, 2026 --

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law Business Wire 5:07 PM
Deadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit Business Wire 2:40 PM
Deadline Approaching: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Business Wire 2:39 PM
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Business Wire 2:37 PM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL) Globe Newswire 11:10 AM
REPL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group Investors - Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm Globe Newswire 11:04 AM
Law Offices of Howard G. Smith Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire About Securities Fraud Class Action Business Wire 10:00 AM
Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action Business Wire 9:00 AM

-- August 6, 2026 --

Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action Business Wire 11:32 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 9:58 PM
REPL CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Replimune Group, Inc. Investors Business Wire 8:06 PM
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen Globe Newswire 4:00 PM

-- August 4, 2026 --

REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations Business Wire 8:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 6:59 PM

-- July 31, 2026 --

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Continues - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Globe Newswire 11:00 AM

-- July 30, 2026 --

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma Globe Newswire 6:15 PM
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:48 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 10:01 AM

-- July 29, 2026 --

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Globe Newswire 8:00 PM
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Business Wire 3:12 PM
Replimune Group Inc. (REPL) Shareholders Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Business Wire 3:04 PM

-- July 28, 2026 --

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz Business Wire 8:40 PM
Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document Globe Newswire 6:21 PM

-- July 15, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL) Globe Newswire 11:28 AM

-- June 29, 2026 --

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- June 26, 2026 --

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma Globe Newswire 8:00 AM

-- May 31, 2026 --

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting Globe Newswire 8:00 AM

-- May 30, 2026 --

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting Globe Newswire 8:00 AM

-- May 29, 2026 --

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA Globe Newswire 8:00 AM

-- May 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 6:07 PM

-- May 17, 2026 --

REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 9:49 PM

-- May 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 8:15 PM

-- May 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 5:24 PM

-- April 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 9:42 PM

-- April 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 5:25 PM

-- April 27, 2026 --

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 8:00 AM

-- April 21, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 4:42 PM

-- April 13, 2026 --

Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 7:45 AM

-- April 10, 2026 --

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma Globe Newswire 5:13 PM
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma Globe Newswire 5:13 PM
Market Data Delayed 15 Minutes